DADC
LUMO

D.A. Davidson & Co’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

D.A. Davidson & Co’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4
Closed – – 2040
2017
Q2 		$0 Hold
4
– – ﹤0.01% 2457
2017
Q1 		$0 Hold
4
– – ﹤0.01% 2513
2016
Q4 		$0 Hold
4
– – ﹤0.01% 2533
2016
Q3 		$0 Sell
4
-9
-69% -$894 ﹤0.01% 2488
2016
Q2 		$1K Hold
13
– – ﹤0.01% 2305
2016
Q1 		$2K Sell
13
-482
-97% -$97.7K ﹤0.01% 2174
2015
Q4 		$161K Sell
495
-4
-0.8% -$1.3K 0.01% 926
2015
Q3 		$160K Sell
499
-11
-2% -$4.83K 0.01% 907
2015
Q2 		$203K Buy
+510
New +$217K 0.01% 866

Other funds holding LUMO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

D.A. Davidson & Co's LUMO Position: Q3 2017 in Review

D.A. Davidson & Co sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q3 2017, closing a stake of 4 shares.

D.A. Davidson & Co first reported a position in LUMO in Q2 2015 and held it in 9 quarters. The position peaked at $203K in Q2 2015. 126 funds tracked by Wall St. Rank hold LUMO as of Q3 2017.

  • D.A. Davidson & Co reported no remaining Lumos Pharma, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • D.A. Davidson & Co sold 4 Lumos Pharma, Inc. Common Stock shares in Q3 2017.
  • D.A. Davidson & Co first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2015 and held it in 9 quarters.
  • D.A. Davidson & Co's Lumos Pharma, Inc. Common Stock position peaked at $203K in Q2 2015.
  • 126 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q3 2017.

Based on D.A. Davidson & Co's 13F filing for Q3 2017, filed 8 Nov 2017.